What DEBRA Research does

DEBRA Research gGmbH is a Munich-based non-profit organization (HRB 271878) that operates worldwide as the translational research and clinical development arm of DEBRA Austria, the Austrian patient organization founded in 1995. The organization's mandate is to advance therapies and ultimately a cure for Epidermolysis Bullosa (EB), a group of rare, painful genetic skin disorders affecting approximately 500,000 people globally, for which no cure currently exists. DEBRA Research pursues this mandate through a portfolio of mechanisms deployed in parallel: structured grant programs for academic researchers, impact-driven equity investments in biotech companies developing EB therapeutics, in-house development via non-profit subsidiaries, and the construction of shared research infrastructure for the broader EB field.

The organization's technology footprint is concentrated in EB-specific rather than general-purpose assets. Core platforms include proprietary or co-developed capabilities in read-through therapy development (ReadOn Therapeutics gGmbH, a joint venture with Nonsense Therapeutics), touchless cutaneous drug delivery (hyliQ® via Dermaliq Therapeutics), protein replacement (NvA-011 / Nova Anchora), biological eye drops for ocular EB (ELK-003 / Eliksa Therapeutics), small-molecule topical therapy for EBS (MP5219 / Mariposa Therapeutics), skin organoid-on-chip disease modeling (SKO-chip, Boston Children's Hospital), and standardized preclinical CRO services (TreatEB at Queen Mary University of London). On the infrastructure side, DEBRA Research funds and coordinates a dedicated clinical trial site at UMC Groningen, contributes to the planned global EB Registry and Clinical Trial Network, and leads the COSEB initiative to harmonize outcome measurement across EB studies.

DEBRA Research does not generate commercial revenue; its funding comprises donations, grants, and recycled returns from impact investments, and its grants, infrastructure, and partnership services are provided free of charge to beneficiaries. The go-to-market model is community-led, relying on the DEBRA International patient organization network for outreach and on collaborative partnerships with academic groups, biotech startups, and pharmaceutical companies to translate science into patient benefit. Therapeutic programs are advanced internally through dedicated non-profit vehicles and then transitioned to commercial partners for further development and eventual market access.

Name

DEBRA Research

Legal name

DEBRA Research gGmbH

Website

https://debra-research.org

Company type

Private

Founded year

1995

Operating status

Operating

Headcount range

1–10 employees

Short description

DEBRA Research is a Munich-based non-profit gGmbH operating worldwide as the research arm of DEBRA Austria, funding and advancing therapies for Epidermolysis Bullosa through grants, impact investments in biotech, in-house development, and shared research infrastructure for the global EB community.

Ownership category

akta.pro rank

Product category

Nonprofit Rare Disease Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA)

akta.pro secondary industries

In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy) (HLAAAIAK), Investigator & Site Training / GCP Support (HLAGACAF)

Keywords

• Rare disease research
• Translational research
• Epidermolysis bullosa therapies
• Nonprofit biotech funding
• Clinical development

Headquarters

HQ city

Munich

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Philanthropic and Impact Investment Funding: DEBRA Research operates as a nonprofit organization. Its funding comes from donations, grants, and impact-driven investments. It deploys capital to advance EB therapies through grant funding, in-house development programs, and equity investments in biotech companies developing EB treatments. The organization does not generate revenue from product sales.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

DEBRA Research is a non-profit research organization (gGmbH) operating as the research arm of DEBRA Austria. It identifies, funds, and advances promising therapies for Epidermolysis Bullosa (EB) through grant funding, in-house drug development via nonprofit subsidiaries (e.g., ReadOn Therapeutics gGmbH), impact investments in biotech companies (Nova Anchora, Eliksa, Mariposa, Dermaliq, Nonsense Therapeutics), and the operation of shared research infrastructure including a preclinical CRO, EB clinical trial sites, and a planned EB Registry and Clinical Trial Network.

Product overview

DEBRA Research is a non-profit organization (gGmbH) operating as the research arm of DEBRA Austria, dedicated to advancing treatments and cures for Epidermolysis Bullosa (EB). Rather than a unified product platform, DEBRA Research offers a portfolio of interconnected services: (1) Impact investments in external biotech companies developing EB therapeutics (ReadOn Therapeutics, Eliksa Therapeutics/ELK-003, Mariposa Therapeutics/MP5219, Nova Anchora/NvA-011, Dermaliq/hyliQ®), (2) In-house development programs through non-profit subsidiaries like ReadOn Therapeutics gGmbH, (3) Research infrastructure services including preclinical CRO capabilities and clinical trial site support, and (4) Grant funding programs for academic and translational EB research. The organization bridges early-stage science to clinical development through strategic funding, scientific expertise, and global network access.

Differentiator

Problem solved

Functional benefit

Brands

• ReadOn Therapeutics: Non-profit biotech company dedicated to advancing read-through therapies for Epidermolysis Bullosa, initially focusing on dystrophic EB caused by nonsense mutations. A joint venture between DEBRA Research and Nonsense Therapeutics.

Products and services

• ReadOn Therapeutics gGmbH A non-profit biotech subsidiary jointly founded with Nonsense Therapeutics Ltd. to develop read-through therapies for Epidermolysis Bullosa, with an initial focus on dystrophic EB caused by nonsense mutations in the collagen VII gene.
• ELK-003 (Eliksa Therapeutics impact investment program) A biological eye drop candidate using a proprietary amniotic fluid secretome formulation licensed from the University of Utah, designed to protect and repair the corneal surface in EB-related ocular complications; currently in pilot clinical study (NCT06713434) in collaboration with DEBRA Chile.
• MP5219 (Mariposa Therapeutics impact investment program) A first-in-class small-molecule topical treatment for Epidermolysis Bullosa Simplex (EBS) developed by Mariposa Therapeutics, designed to activate protective keratin pathways (including keratin 17 and inducible keratins) and strengthen keratinocyte structural resilience.
• NvA-011 (Nova Anchora impact investment program) A recombinant type VII pro-collagen protein replacement therapy for topical application in dystrophic EB (DEB) developed by Nova Anchora LLC, designed to restore defective type VII collagen; received FDA orphan drug designation in 2024.
• Preclinical EB CRO Platform (TreatEB) A preclinical Contract Research Organization offering standardized in vitro and in vivo models, assay development, and efficacy testing capabilities for candidate EB therapies, providing access to academic labs, biotech, and pharma.
• EB Clinical Trial Site Support Support for dedicated EB clinical trial sites, including the University Medical Center Groningen (UMCG) site, which conducts company-sponsored and investigator-initiated EB clinical trials and contributes to the planned global EB Registry and Clinical Trial Network.
• DEBRA Research Grant Programs Structured funding opportunities including Basic Science & Research Grants and ad-hoc grants supporting innovative EB research projects from early scientific discovery through translational development and clinical application.

Quantifiable outcome

• FDA orphan drug designation granted to NvA-011 (Nova Anchora) in 2024 for dystrophic EB
• +5 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• University Medical Center Groningen (UMCG)coreStrategic or Co-development Partner · 19 January 2026DEBRA Research and UMC Groningen established a dedicated EB clinical trial site at UMCG, strengthening translational EB research infrastructure and expanding clinical trial capacity. Under the leadership of Principal Investigator Dr. Marieke C. Bolling, the site is equipped to conduct both company-sponsored and investigator-initiated clinical trials. The site will contribute to the planned EB Registry and Clinical Trial Network, and to the international COSEB project for harmonizing outcome measurement. DEBRA Research is also funding the COSEB project.
• Nonsense Therapeutics (Nonsense Tx)coreStrategic or Co-development Partner · 22 September 2025DEBRA Research and Nonsense Therapeutics jointly founded ReadOn Therapeutics gGmbH, a nonprofit company dedicated to advancing read-through therapies for EB. The initial focus is on dystrophic EB caused by nonsense mutations in the collagen VII gene. ReadOn Therapeutics carries out preclinical programs and IND-enabling studies with a goal to be clinic-ready in under 3 years. DEBRA Research consolidates drug development activities for read-through molecules within this dedicated nonprofit biotech.
• Dermaliq TherapeuticscoreStrategic or Co-development Partner · 28 May 2025DEBRA Research entered a strategic, non-exclusive collaboration with Dermaliq Therapeutics to advance cutaneous drug delivery for EB. Initial programs focus on wound healing, anti-itch therapies, and prophylactic treatments. Dermaliq's proprietary hyliQ® technology enables touchless delivery of therapeutic compounds to fragile, sensitive or disease-affected skin. DEBRA Research has also made a strategic investment in Dermaliq as part of the agreement. DEBRA Research's Dr. Christoph Coch described the partnership as aligning with the mission to accelerate high-impact therapies for people living with EB.
• Queen Mary University of London (TreatEB)coreStrategic or Co-development PartnerDEBRA Research collaborates with Queen Mary University of London to support the TreatEB preclinical EB CRO platform, enabling the teams of Dr. Emanuel Rognoni and Dr. Matthew Caley to make their preclinical capabilities accessible to the wider EB research community including academic labs, biotech, and pharma companies. This provides standardized in vitro and in vivo models, assay development, and efficacy testing for candidate EB therapies.
• DEBRA ChilecoreStrategic or Co-development PartnerDEBRA Research collaborated with DEBRA Chile to conduct the pilot clinical study for ELK-003 (Eliksa Therapeutics) in EB patients. DEBRA Chile is a nonprofit patient organization providing comprehensive patient care, advocacy, and access to innovative treatments for EB patients in Chile. It is part of the global DEBRA International network.
• Stanford University / Prof. Peter MarinkovichcoreStrategic or Co-development PartnerStanford University (through Prof. Peter Marinkovich, Associate Professor of Dermatology at Stanford Medicine) co-founded Nova Anchora LLC in 2021 and licensed foundational technology to the company. Prof. Marinkovich is a leading expert in the EB field. DEBRA Research invested alongside Stanford University in Nova Anchora.
• DEBRA Netherlands / Stichting VlinderkindminorStrategic or Co-development PartnerDEBRA Research's collaboration with UMC Groningen is coordinated in close partnership with Stichting Vlinderkind and DEBRA Netherlands, key EB nonprofit organizations in the Netherlands. These organizations support the interdisciplinary team within the Department of Dermatology at UMCG.
• EB House AustriaminorStrategic or Co-development PartnerEB House Austria, located at Salzburg University Hospital, is the world's first special clinic for 'butterfly children' (EB patients). DEBRA Research collaborates with EB House Austria on a clinical observation project exploring transcutaneous vagus nerve stimulation (tVNS) for sleep disturbances in EB patients. EB House Austria is funded by DEBRA Austria.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Abe Fund: Mission-driven investment fund founded by Alex Hersham whose stated purpose is to make EB a near-normal life. Co-investor with DEBRA Research in Eliksa Therapeutics, providing a near-identical impact-investing model peer operating in the same disease.
• EB Research Partnership (EBRP): Describes itself as the largest global nonprofit funder of EB research, co-investing with DEBRA Research in companies such as Nova Anchora and Eliksa Therapeutics. Operates a venture philanthropy model very similar to DEBRA Research, advancing EB therapies from discovery through clinical development.
• Stichting Vlinderkind / DEBRA Netherlands: Dutch EB nonprofit that co-funds the interdisciplinary EB team at UMC Groningen alongside DEBRA Research. Functions as a national-association peer with the same patient-to-research translation model in a specific European geography.
• DEBRA International: Global umbrella network of national EB patient organizations (including DEBRA Austria, DEBRA UK, DEBRA Chile, DEBRA Netherlands). DEBRA Research operates as DEBRA Austria's research arm, making DEBRA International the structural parent-network peer with overlapping mission, ecosystem access, and patient-community reach.
• Epidermolysis Bullosa Medical Research Foundation (EBMRF): US nonprofit founded in 1991 funding critical EB research and awareness, with much of its administration performed voluntarily. Co-invests with DEBRA Research in Nova Anchora and Eliksa Therapeutics, functioning as a like-for-like mission-aligned funding peer.
• CureEB: UK-based charity dedicated to finding treatments and a cure for all forms of EB with an emphasis on gene-modifying technologies. Repeated co-investor with DEBRA Research in Nova Anchora and Eliksa Therapeutics, serving as a near-perfect functional peer on the EB-focused venture philanthropy axis.

Broad incumbents

• Cystic Fibrosis Foundation: Large US nonprofit that pioneered venture philanthropy in rare disease research, historically funding and commercializing CF therapies through royalty-based models. Functionally analogous to DEBRA Research as a disease-focused translational research foundation but at materially greater scale and in a different (though still rare) disease.
• Muscular Dystrophy Association (MDA): US nonprofit funding neuromuscular disease research and supporting clinical infrastructure across multiple rare disease subtypes. Comparable to DEBRA Research as a multi-decade rare-disease translational research funder, though with broader disease scope and consumer-facing fundraising model.

Regional players

• EB House Austria (EB Haus Austria): The world's first specialized clinic for EB patients at Salzburg University Hospital, funded by DEBRA Austria. Comparable to DEBRA Research as a translational hub for EB but focused on clinical care delivery and observational studies (e.g., tVNS for EB-related sleep disturbance) rather than drug investment.

Emerging players

• ALS Therapy Development Institute (ALS TDI): Nonprofit biotech that operates its own drug discovery laboratory to develop treatments for ALS. Comparable to DEBRA Research in its in-house translational research and clinical development mission within a single rare disease, though ALS TDI conducts discovery directly rather than primarily funding portfolio companies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/debra-research

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments4 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DEBRA Research